Navigation Links
Genethon and Children's Hospital Boston Get FDA approval for a Wiskott Aldrich Gene Therapy Trial
Date:7/21/2011

BOSTON, July 21, 2011 /PRNewswire-USNewswire/ -- The U.S. Food & Drug Administration (FDA) approved the launching in the U.S. of a clinical trial for gene therapy for a rare immunodeficiency, Wiskott-Aldrich syndrome (WAS). After its implementation in Paris and London, this trial based on preclinical research performed at Genethon (Evry, France) which also manufactures the GMP gene therapy product, is now going to be launched in Boston. It's one of the first international clinical trials using a gene therapy treatment for a rare disease.  

Earlier this year, Genethon, the not-for-profit biotherapy laboratory funded by the French Muscular Dystrophy Association (AFM) thanks to the donations collected during the French Telethon, and Children's Hospital Boston announced that they have initiated a partnership to conduct a gene therapy clinical trial for Wiskott-Aldrich Syndrome (WAS), a severe immunodeficiency disease leading to death before adulthood. Genethon is sponsoring parallel trials at Great Ormond Street Hospital in London and Hopital Necker-Enfants Malades in Paris and is supplying the vector for all clinical sites. In total, this trial will involve fifteen patients, five for each site, who will be treated by 2013-2014. The sites in London and Paris have already started treating patients under this protocol. Altogether, the WAS gene therapy trials in London, Paris and Boston will constitute a unique multicenter collaboration to accelerate the testing of new advanced therapies for rare conditions.

The Boston trial will be funded by the National Heart, Lung and Blood Institute (NHLBI) through its Gene Therapy Resource Program (GTRP). Principal investigators at Children's are Sung-Yun Pai, MD, Division of Hematology/Oncology, and Luigi Notarangelo, MD, director, Research and Molecular Diagnosis Program on Primary Immunodeficiencies, Division of Immunology. David A. Williams, MD, chief of the Division of Hematology/Oncology and director o
'/>"/>

SOURCE Children's Hospital Boston
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Pradaxa® (dabigatran etexilate mesylate) Capsules Now on Formulary at Nations Top Heart Hospitals
2. Axial Biotech Signs Agreement With Shriners Hospital for Children
3. Texas Childrens Hospital is First Pediatric Hospital in the Nation to Implant Artificial Heart
4. Paoli Hospital Pioneers New Treatment for Uterine Fibroids and Malformations
5. Baylor College of Medicine and Texas Childrens Hospital Neuroscientist Dr. Huda Zoghbi Awarded Gruber Neuroscience Prize
6. Hospital for Special Surgery to Host International Arthritis Summit: Frontiers in Osteoarthritis Research, Prevention and Care
7. St. Lukes Hospital & Health Network Selects CareTech Solutions to Provide Proactive Monitoring of Hospital IT Infrastructure
8. BioNeutral to Premier its EPA-Approved Ygiene® 206 Hospital-Grade Disinfectant at the Annual 2011 APIC Conference, While Community Health of South Florida Begins Product Review
9. SynapDx Corporation Licenses Autism Diagnostic Discoveries From Childrens Hospital Boston
10. Newly Published Study Shows Dramatic Reduction in Hospital Acquired Infections
11. WARFARIN Study Launched at WellStar Health System to Assess Impact of Genetic Testing in Reducing Hospitalizations and Deaths Caused by Warfarin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... Burlington, MA (PRWEB) October 31, 2014 ... is hosting a free learning webinar to introduce its ... managers, standards directors and biostatisticians. , Launched in September, ... the company's suite of clinical trial automation tools. For ... in a web browser. And by introducing Formations – ...
(Date:10/31/2014)... Brady (NYSE:BRC), a global leader in product ... video testimonial on the effectiveness of its FreezerBondz™ ... at the BloodCenter of Wisconsin discusses the challenges she ... of thousands of samples, and how the durability of ... we design our label materials with the harsh conditions ...
(Date:10/31/2014)... , Oct. 31, 2014  Tavistock Development ... by Tavistock Group, celebrated the groundbreaking of the ... City. The 92,000-square-foot, three-story facility ... Central Florida designed specifically for life ... the heart of the 650-acre Lake Nona Medical ...
(Date:10/30/2014)... 2014 Investor-Edge has initiated coverage ... ONVO), Medivation Inc. (NASDAQ: MDVN ), Pharmacyclics ... (NYSE MKT: SYN), and Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD). ... at: http://investor-edge.com/register . On Wednesday, October ... 0.33%, the Dow Jones Industrial Average declined 0.18%, to ...
Breaking Biology Technology:Formedix to Introduce "Revolutionary" Clinical Trial Automation Software with Learning Webinar 2Brady Debuts New Lab Label Testimonial Video 2GuideWell Innovation Center Groundbreaking Hosted by Tavistock Development Company at Lake Nona Medical City 2GuideWell Innovation Center Groundbreaking Hosted by Tavistock Development Company at Lake Nona Medical City 3Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 2Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 3Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 4Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 5
... Inc.,(Nasdaq: VSCP ), a leading provider of ... 25, 2009 it will release its 2008,fourth quarter and ... 2008. The company will host a conference call ... 11:00 a.m. EST. , VirtualScopics, ...
... Include: - Initiation of development activities to ... Receipt of GRAS (Generally Recognized As Safe) ... commercialization in the U.S. and elsewhere- New ... Continued activities to support regulatory filings for ...
... LAIYANG, China, Feb. 12 /PRNewswire-Asia-FirstCall/ -- Genesis,Pharmaceuticals Enterprises, Inc. ... pharmaceutical company with its principal operations,in the People,s Republic ... conference call at 9:00 a.m. Eastern on Tuesday, February ... ended December 31, 2008 of,its fiscal year 2009. , ...
Cached Biology Technology:VirtualScopics Schedules Fourth Quarter 2008 Earnings Announcement 2VirtualScopics Schedules Fourth Quarter 2008 Earnings Announcement 3SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 2SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 3SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 4SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 5SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 6SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 7SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 8SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 9SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 10SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 11SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 12SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 13SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 14Genesis Pharmaceuticals Announces Conference Call to Discuss Results for its Second Quarter of FY 2009 2Genesis Pharmaceuticals Announces Conference Call to Discuss Results for its Second Quarter of FY 2009 3
(Date:10/30/2014)... DALLAS , Oct. 29, 2014 /PRNewswire/ ... and criminal justice technology solutions for public ... that it has deployed exciting enhancements to ... data analytics to provide actionable intelligence and ... Technologies continues to drive technological innovation through ...
(Date:10/29/2014)... registration is open for the Society ... Meeting. SIR 2015 is the one place ... and related health care professionals can come ... science and technologies being presented, discussed and ... in minimally invasive, image-guided medicine, SIR 2015 ...
(Date:10/29/2014)... City on September 19, 2014, leading geneticist and humanitarian ... Genome Sciences and Medicine at the University of Washington ... Tel Aviv University, was awarded the 2014 Lasker-Koshland Special ... her honorary degree from TAU, Prof. King was the ... and for the past 18 years she has been ...
Breaking Biology News(10 mins):Securus Technologies Adds Advanced Features to Its Industry-Leading Investigative Analytics Product 2SIR 2015: Interventional radiology shapes tomorrow's medicine 2Geneticist and humanitarian: Prof. Mary-Claire King receives Lasker Award 2
... in Biomed Central,s open access journal Journal of ... brain to develop Alzheimer,s disease. To date ... of inflammation in Alzheimer,s disease (AD), especially because trials ... ADAPT (The Alzheimer`s Disease Anti-inflammatory Prevention Trial) trial was ...
... Physics World, Steve Haake, director of the Centre for Sports ... the men,s 100 m sprint will be one event not ... the "performance-improvement index", which uses very simple physics to compare ... the last 100 years. The model shows that the ...
... next "next-gen" technology in genome sequencing has gotten a major ... Spring Harbor Laboratory (CSHL) and collaborators today published results of ... was recently introduced but whose use has so far been ... CSHL Assistant Professor Michael Schatz and Adam Phillippy and Sergey ...
Cached Biology News:Physics confirms sprinters are performing better than ever before 2An error-eliminating fix overcomes big problem in '3rd-gen' genome sequencing 2An error-eliminating fix overcomes big problem in '3rd-gen' genome sequencing 3
... The new D-LUX Detection Platform ... to provide the most sensitive, specific, ... qPCR. Invitrogens D-LUX Detection Platform offers ... equal to TaqMan probes, high signal/background ...
Provides continuous mixing action. For use with tubes, vials, and other containers...
... is aseptically collected via cardiac puncture from 3 ... mixed sex). It is then centrifuged and frozen ... filtered and bottled at 4C then stored at ... HAVE ALWAYS USED PEL-FREEZ COMPLEMENT, YOU CAN NOW ...
Modified and insect cell culture tested....
Biology Products: